Company Profile
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.
Latest News

Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls

Anteris Technologies appoints Brent Moen as chief financial officer

Anteris to Present at September Healthcare Investor Conferences
Anteris Technologies Q2 Loss Narrows, Net Sales Rise

Anteris Technologies Announces Results for the Second Quarter of 2026
Related stocks
Key Metrics & Overview
Detailed metrics & financial data of the company
🛡️ Risk & Structural Analysis
Multi-Factor Risk Model & Market Data